Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Meningococcal Vaccines Industry By 2029?

The market size for meningococcal vaccines has exhibited substantial growth recently. The market value is anticipated to increase from $3.89 billion in 2024 to $4.26 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 9.3%. Factors such as disease occurrence rates, trends in global travel, the state of health care infrastructure, the level of preparedness for epidemics, and the extent of health insurance coverage have all contributed to this historical growth.

In the coming years, the meningococcal vaccines market is projected to witness robust expansion. The market is set to escalate to “$6.05 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. The projected growth in this duration can be ascribed to the appearance of new strains, escalating globalization, burgeoning healthcare investments, health initiatives, and alteration in regulatory frameworks. Key trends expected throughout the forecast period encompass customized vaccines, electronic vaccination records, gene alteration technologies, multi-valent vaccines, and recurring-subscription vaccine models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

Which Demand Drivers Are Strengthening The Meningococcal Vaccines Market?

The anticipated surge in healthcare expenditure is predicted to fuel the expansion of the meningococcal vaccine market. The term healthcare encompasses facilities such as residences for care, nursing homes, intermediate care institutions for those suffering from mental illnesses or retardation. The high cost associated with newer iterations of vaccines, in comparison to earlier versions, has sparked debates about the economic viability of these advancements. The comprehensive assessment of the social and economic boons brought about by vaccination is increasingly being explored in academic discourse around vaccine valuation. As an example, a May 2022 report from the American Medical Association, a prominent association and advocacy group for physicians and medical students in the United States, revealed that healthcare expenditure in the country had grown by 9.7%, amounting to $4.1 trillion or $12,530 per capita. This rate of growth substantially overpowers that of 2019, which was at 4.3%. Consequently, a rise in healthcare spending is propelling the progress of the meningococcal vaccine market.

What Are The Key Segment Trends Observed In The Meningococcal Vaccines Market?

The meningococcal vaccines market covered in this report is segmented –

1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine

2) By Serotype: Men Acwy, Men B/Bc, Men C

3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults

4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels

5) By End user: Hospitals, Research, Academic Institutes

Subsegments:

1) By Meningococcal Conjugate Vaccine: Quadrivalent Conjugate Vaccine (MenACWY), Bivalent Conjugate Vaccine

2) By Polysaccharide Vaccine: Meningococcal Polysaccharide Vaccine (MPSV4), Group C Polysaccharide Vaccine

3) By Subcapsular Vaccine: Meningococcal B Vaccine (MenB), Combination Subcapsular Vaccines

Which Disruptive Trends Are Driving Change Across The Meningococcal Vaccines Market?

Leading businesses in the meningococcal vaccines market are focusing on the creation of novel vaccines to prevent various serogroups, aiming to enhance their market profitability. Meningococcal vaccines serve as a preventative method to shield people from infections prompted by certain serogroups of the bacteria Neisseria meningitidis. For instance, in October 2023, Pfizer Inc., an American pharmaceutical firm, obtained FDA approval for the vaccine PENBRAYA. PENBRAYA offers substantial serogroup coverage and is the most exhaustive meningococcal vaccine authorized in the U.S, providing protection against groups A, B, C, W, and Y. The FDA approval is based on substantial Phase 2 and 3 trial data that proves it’s not inferior in immunogenicity to Trumenba + Menveo across all serogroups, in addition to a favourable safety profile. In September 2022, Pfizer announced encouraging results from a Phase 3 trial comparing the safety, tolerability, and immunogenicity of PENBRAYA with other licensed meningococcal vaccines.

Which Companies Are Contributing Significantly To The Meningococcal Vaccines Market Growth?

Major companies operating in the meningococcal vaccines market include Pfizer Inc., GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Bio-Manguinhos, Walvax Biotechnology Co. Ltd., Bavarian Nordic A/S, Hualan Biological Engineering Inc., China National Pharmaceutical Group (Sinopharm), Bharat Biotech, Incepta Pharmaceuticals Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co. Ltd., Biokangtai, Biomed Pvt Ltd., Biocine SCL, Panacea Biotec Ltd., Grifols S.A., CSL Limited, Minhai Biotechnology Co. Ltd., Chiron Behring Vaccines Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Which Region Is Forecasted To Lead The Meningococcal Vaccines Market In The Coming Years?

North America was the largest region in the meningococcal vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the meningococcal vaccines market report during the forecast period. The regions covered in the meningococcal vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8013&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model